Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
29. Juli 2021 17:00 ET
|
Cyclerion Therapeutics, Inc.
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive...
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
22. Juli 2021 16:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
08. Juli 2021 16:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two...
Cyclerion Therapeutics Announces $18 Million Private Placement
04. Juni 2021 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
04. Juni 2021 08:00 ET
|
Cyclerion Therapeutics, Inc.
Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties Praliciguat out-licensing further enables...
Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
27. Mai 2021 16:30 ET
|
Cyclerion Therapeutics, Inc.
Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator Oral, once-daily CY6463 is being developed for neurological diseases...
Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
25. Mai 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual...
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
27. April 2021 09:00 ET
|
Cyclerion Therapeutics, Inc.
Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and...
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
26. April 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
21. April 2021 07:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...